Suarez et al. developed a combinatorial immunotherapy that consisted of human CD28 anti-carbonic anhydrase IX (CAIX)-targeted CAR-T cells engineered to secrete human anti-PD-L1 antibodies at the tumor site using a single bicistronic lentiviral vector [50]. Here, CD28 is linked to neoplasm.